Boehringer Ingelheim has introduced VETMEDIN Solution, the first oral solution approved by the US Food and Drug Administration (FDA) for the management of congestive heart failure (CHF) in dogs due to MMVD or DCM.

Unfortunately, heart disease in dogs is common, affecting approximately 10 percent of dogs in their lifetime.

Most frequently, dogs are affected by myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM), both which may progress to CHF, characterized by the inability of the heart to effectively pump blood throughout the body.

Now pet owners have a convenient, new management option to support the hearts of dogs with CHF: a liquid version of VETMEDIN, one of the leading canine cardiology medications in the world. Previous studies have shown that VETMEDIN could help increase the survival time and quality of life in dogs due to MMVD or DCM.

VETMEDIN Solution (pimobendan oral solution) and VETMEDIN (pimobendan) Chewable Tablets are for use in dogs with clinical evidence of heart failure only and should not be given in case of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons.

"We continue to deliver new innovations rooted in robust clinical evidence to help more pets. We know some dogs and pet owners may prefer a liquid medication, especially for smaller dogs. With VETMEDIN® Solution, an easy-to- use liquid formulation, we can help more dogs with heart disease have longer survival and live better lives," said Daniel Watkins, VP US Pet Business, Boehringer Ingelheim.

VETMEDIN Solution, now available in the US, provides the same dual mode of action as VETMEDIN® Chewable Tablets. The flavorless, twice-daily liquid oral solution should be administered directly into the dog's mouth.

Since VETMEDIN was first introduced 25 years ago, dogs and their owners around the world have enjoyed more than 1 million years of additional life to love.4 VETMEDIN Chewable Tablets are approved for the management of the signs of mild, moderate, or severe CHF in dogs due to clinical MMVD or DCM. VETMEDIN.